Display options
Cite
Pupo GM, Boyd SC, Fung C, et al. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered . Biomark Res. 2017;5:17doi: 10.1186/s40364-017-0098-3.
Pupo, G. M., Boyd, S. C., Fung, C., Carlino, M. S., Menzies, A. M., Pedersen, B., Johansson, P., Hayward, N. K., Kefford, R. F., Scolyer, R. A., Long, G. V., & Rizos, H. (2017). Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered . Biomarker research, 517. https://doi.org/10.1186/s40364-017-0098-3
Pupo, Gulietta M, et al. "Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered ." Biomarker research vol. 5 (2017): 17. doi: https://doi.org/10.1186/s40364-017-0098-3
Pupo GM, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered . Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017. PMID: 28503307; PMCID: PMC5426037.
Copy Download .nbib Format: NLM
Share it on

Biomark Res. 2017 May 11;5:17. doi: 10.1186/s40364-017-0098-3. eCollection 2017.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered .

Biomarker research

Gulietta M Pupo, Suzanah C Boyd, Carina Fung, Matteo S Carlino, Alexander M Menzies, Bernadette Pedersen, Peter Johansson, Nicholas K Hayward, Richard F Kefford, Richard A Scolyer, Georgina V Long, Helen Rizos

Affiliations

  1. Centre for Cancer Research, The Westmead Millennium Institute for Medical Research, University of Sydney, Westmead Hospital, Westmead, NSW Australia.
  2. Melanoma Institute Australia, Sydney, NSW Australia.
  3. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW Australia.
  4. Departments of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW Australia.
  5. Disciplines of Medicine, Sydney Medical School, The University of Sydney, Sydney, NSW Australia.
  6. Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD Australia.
  7. Disciplines of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW Australia.
  8. Departments of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital, Camperdown, NSW Australia.

PMID: 28503307 PMCID: PMC5426037 DOI: 10.1186/s40364-017-0098-3

Abstract

Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4-8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of

Keywords: BRAF inhibitor; BRAF splicing; Dabrafenib; Melanoma; Resistance

References

  1. Nature. 2011 Nov 23;480(7377):387-90 - PubMed
  2. Nat Struct Mol Biol. 2012 Jun 17;19(7):719-21 - PubMed
  3. Eur J Cancer. 2015 Dec;51(18):2792-9 - PubMed
  4. Nucleic Acids Res. 2008 Apr;36(7):2257-67 - PubMed
  5. Mol Oncol. 2014 May;8(3):544-54 - PubMed
  6. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  7. Nucleic Acids Res. 2009 May;37(9):e67 - PubMed
  8. Clin Cancer Res. 2014 Apr 1;20(7):1965-77 - PubMed
  9. Lancet. 2012 Jul 28;380(9839):358-65 - PubMed
  10. Cancer Discov. 2014 Jan;4(1):80-93 - PubMed
  11. Nat Commun. 2014 Dec 02;5:5694 - PubMed
  12. Nat Commun. 2015 May 14;6:7103 - PubMed

Publication Types